Effect of IL-17A blockade with secukinumab in autoimmune diseases.
about
Genetics of psoriasis and pharmacogenetics of biological drugsK/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory ArthritisAssociation between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel DiseaseTh17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsTargeting Th17 Cells with Small Molecules and Small Interference RNANew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsIL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A TherapiesIL-17 family: cytokines, receptors and signalingTargeting of interleukin-17 in the treatment of psoriasisThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testingSecukinumab: A New Treatment Option for Psoriatic ArthritisNew targets in psoriatic arthritisInvolvement of interleukin-17A-induced hypercontractility of intestinal smooth muscle cells in persistent gut motor dysfunctionSecukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms.An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition.Animal models for candidiasisPharmacotherapy for uveitis: current management and emerging therapy.Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitisCytokine-modulating strategies and newer cytokine targets for arthritis therapy.DRB1*0402 may influence arthritis by promoting naive CD4+ T-cell differentiation in to regulatory T cells.Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollutionThe anaphase-promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction.Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?Relationship of CD146 expression to secretion of interleukin (IL)-17, IL-22 and interferon-γ by CD4(+) T cells in patients with inflammatory arthritisAnti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodiesSignaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis.The danger model approach to the pathogenesis of the rheumatic diseases.Mechanisms of human autoimmunity.MCPIP1 Endoribonuclease Activity Negatively Regulates Interleukin-17-Mediated Signaling and Inflammation.IκBζ is a key driver in the development of psoriasis.The Role of IL-17 and Th17 Lymphocytes in Autoimmune DiseasesCCAAT/Enhancer-binding protein β promotes pathogenesis of EAE.CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell PathogenicitySecukinumab.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment.Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.
P2860
Q21284816-4A999463-613A-4069-B7A5-61F7686DF82EQ26745541-597DD38C-2DBD-460F-BF54-48645F5EC5EFQ26767247-D677B16C-5830-456B-8636-162242AEF991Q26768649-6F8ECD89-F308-4A43-8BB9-024096F9FD01Q26770523-1D5266D1-9A08-43C5-952E-17FDB646F161Q26800937-CBC49DD2-48ED-426B-A0B6-A287E6E99E78Q26830943-D5E40E74-A24B-455C-9309-98F5CD7BCF22Q26860251-8CB128BF-1494-4F29-BC4A-91EB1A00B317Q27026324-84D98D72-2B4D-4ED6-8C80-00D2569602F9Q27687800-4FE73FB0-FAA3-49D7-8067-41743BBF55C2Q28066204-39D9E4DE-8254-42BF-86C1-72686D3A281DQ28069592-6E57FFC0-B379-4D7C-8EF7-7560C68A5A68Q33567657-83E21C52-0B96-49DE-A8BC-AE3FCAC80014Q33574665-41891CD0-0493-494D-AD3D-5F60F67F39A6Q33791610-78F8F290-B590-46A4-B335-CB5704DD7EA0Q33798102-742370BA-16A8-42C6-A6A5-880998B9FFE6Q33870482-31B5A504-C333-418B-803A-A3E68808788AQ34274075-AD1971C4-4B71-4069-903E-470B836C062BQ34437894-A6A55A25-6A11-45CF-89A6-07D7772F9084Q34456715-D46FEFB5-9B17-40ED-BA43-E3A007BF0AD3Q34516919-5F572C72-72DF-4BB4-A833-7476D3F5A25DQ34745617-0707B5DD-2857-40E3-92E5-18763C0C1E19Q34782588-233DD668-2F88-4C50-89A0-2A6A89407E47Q34906387-98147F94-B15A-4317-917F-F891AEED42C4Q34937925-9D94FB03-B939-4414-A928-9557FF1174DAQ35111378-FA1B08B4-8BE6-499E-9B9A-F20080BA15E6Q35146363-366A5D4D-35A5-4052-A972-66A2F989F804Q35301398-78543787-AB1C-4488-AE2C-C1CF6F8FF2CFQ35564107-7FF1F9D1-8DC0-41F7-8696-1F69A337AF3EQ35899439-B201F51A-D4F6-4542-8B3B-24B9555A392FQ36073357-1A02B5C2-6BAE-47D3-94D0-C35F25F94A4BQ36238508-0A206351-75C7-47AC-A713-5193B06B41F0Q36249305-FF2B5004-D26B-4CEA-85AC-A3FB03999DA5Q36249964-A65A2037-0AA9-4B55-8758-CEA6076E6743Q36352360-C80CF28A-F648-4191-B578-7D9D87EF66F4Q36391509-97BA6542-FE61-413E-B7E6-7A95F8A55B51Q37019872-765B73AF-0ED2-4078-8038-276F54CEC3FFQ37111268-FC7C342D-85D6-496C-B0B7-7E3097758BF2Q37202359-46AEE283-1697-43D7-B3D1-DF0D0B1835CFQ37258941-57BABC87-EB29-460E-970F-D5FB37C18186
P2860
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
@en
type
label
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
@en
prefLabel
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
@en
P2093
P1476
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
@en
P2093
Christian Antoni
David M Lee
Dhavalkumar D Patel
Frank Kolbinger
P304
P356
10.1136/ANNRHEUMDIS-2012-202371
P407
P478
72 Suppl 2
P577
2012-12-19T00:00:00Z